Your browser doesn't support javascript.
Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19).
Khouja, Tumader; Mitsantisuk, Kannop; Tadrous, Mina; Suda, Katie J.
  • Khouja T; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Mitsantisuk K; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Tadrous M; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
  • Suda KJ; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
J Antimicrob Chemother ; 77(5): 1491-1499, 2022 04 27.
Article in English | MEDLINE | ID: covidwho-1704938
ABSTRACT

BACKGROUND:

Little is known about the effect of the COVID-19 pandemic on antimicrobial consumption worldwide.

OBJECTIVES:

To describe the impact of the WHO Global Action Plan on Antimicrobial Resistance (GAP-AMR) on antimicrobial consumption pre-pandemic and to evaluate the impact of the COVID-19 pandemic on antimicrobial consumption worldwide.

METHODS:

A cross-sectional time-series analysis using a dataset of monthly purchases of antimicrobials (antibiotics, antivirals and antifungals) from August 2014 to August 2020. Antimicrobial consumption per 1000 population was assessed pre-pandemic by economic development status using linear regression models. Interventional autoregressive integrated moving average (ARIMA) models tested for significant changes with pandemic declaration (March 2020) and during its first stage from April to August 2020, worldwide and by country development status.

RESULTS:

Prior to the pandemic, antimicrobial consumption decreased worldwide, with a greater apparent decrease in developed versus developing countries (-8.4%, P = 0.020 versus -1.2%, P = 0.660). Relative to 2019, antimicrobial consumption increased by 11.2%, P < 0.001 in March 2020. The greatest increase was for antivirals in both developed and developing countries (48.2%, P < 0.001; 110.0%, P < 0.001) followed by antibiotics (6.9%, P < 0.001; 5.9%, P = 0.003). From April to August 2020, antimicrobial consumption decreased worldwide by 18.7% (P < 0.001) compared with the previous year. Specifically, antibiotic consumption significantly decreased in both developed and developing countries (-28.0%, P < 0.001; -16.8%, P < 0.001).

CONCLUSIONS:

The global decrease in antimicrobial consumption pre-pandemic suggests a positive impact of the WHO GAP-AMR. During the pandemic, an initial increase in antimicrobial consumption was followed by a decrease worldwide. AMR plans should specify measures to ensure full implementation of AMR efforts during health crises such as the COVID-19 pandemic.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Anti-Infective Agents Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Humans Language: English Journal: J Antimicrob Chemother Year: 2022 Document Type: Article Affiliation country: Jac

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Anti-Infective Agents Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Humans Language: English Journal: J Antimicrob Chemother Year: 2022 Document Type: Article Affiliation country: Jac